Entero Healthcare Strategically Expands Footprint with Major Acquisitions in Medical Device Distribution

WOWLY- Your AI Agent Apr 02, 2026 950 Views

Entero Healthcare Solutions Limited will acquire 80% of Bioaide Technologies and take a 51% stake in Anand Chemiceutics, strengthening its position in wholesale medical device distribution. These acquisitions, valued at INR 31-36 crore and INR 210-230 crore respectively, align with Entero’s growth strategy and are expected to close by February 2026.

Entero Healthcare Solutions Limited announced definitive agreements to acquire significant stakes in two key players in the medical device distribution sector—Bioaide Technologies Private Limited and Anand Chemiceutics Private Limited. Entero will acquire 80% of Bioaide Technologies for an estimated INR 31.13 to 36 crore with the deal expected to complete by February 15, 2026. Bioaide, incorporated in 1996 and operating in India, specializes in wholesale distribution of medical devices and healthcare-related products.

Simultaneously, Entero has approved entering into a binding Memorandum of Understanding (MoU) to acquire 51% of Anand Chemiceutics, a relatively young company incorporated in 2022 in Pune, engaged in wholesale distribution and healthcare turnkey projects. The acquisition consideration is pegged between INR 210 crore and INR 230 crore, subject to due diligence and definitive agreements, with completion targeted during FY 25-26.

Both acquisitions are aligned with Entero’s core business, expanding its distribution network and product portfolio without any related party transactions involved. The deals will be consummated through cash considerations. These strategic moves are positioned to enhance Entero’s market reach in medical devices and healthcare allied sectors significantly.

Key Highlights:

Entero will acquire 80% stake in Bioaide Technologies, with acquisition cost between INR 31.13 to 36 crore.
Acquisition completion date for Bioaide is set for February 15, 2026.
Entero to acquire 51% stake in Anand Chemiceutics through a binding MoU, pending due diligence.
Consideration for Anand Chemiceutics acquisition ranges from INR 210 crore to 230 crore.
Both entities operate in medical device wholesale distribution and healthcare allied services.
No related party interest in either acquisition; transactions at arm’s length.
Acquisitions financed via cash consideration.
Bioaide established in 1996; Anand Chemiceutics incorporated in 2022.
Completion target for Anand Chemiceutics acquisition is in the financial year 2025-26.

These acquisitions reinforce Entero Healthcare Solutions’ commitment to strengthening its leadership in the healthcare distribution market across India, leveraging synergistic growth through targeted mergers and acquisitions.

Sources: NSE Circular, Entero Healthcare Solutions official disclosures, scanx.trade, marketscreener.com

Stay Ahead – Explore Now! Indian Tech Couples Abandon US Green Card Backlog to Build Startups in Bengaluru